Additional Local Therapy for Liver Metastases in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Systemic PSMA-Targeted Therapy. | LitMetric
The aim of this study was to evaluate the efficacy of Lu-prostate-specific membrane antigen (PSMA)-617 (Lu-PSMA) and selective internal radiation therapy (SIRT) for the treatment of liver metastases of castration-resistant prostate cancer. Safety and survival of patients with metastatic castration-resistant prostate cancer and liver metastases assigned to Lu-PSMA alone ( = 31) or in combination with SIRT ( = 5) were retrospectively analyzed. Additionally, a subgroup ( = 10) was analyzed using morphologic and molecular response criteria. Median estimated survival was 5.7 mo for Lu-PSMA alone and 8.4 mo for combined sequential Lu-PSMA and SIRT. Lu-PSMA achieved discordant therapy responses with both regressive and progressive liver metastases in the same patient (best vs. worst responding metastases per patient: -35% vs. +63% diameter change; < 0.05). SIRT was superior to Lu-PSMA for the treatment of liver metastases (0% vs. 56% progression). The combination of Lu-PSMA and SIRT is efficient and feasible for the treatment of advanced prostate cancer. Lu-PSMA alone seems to have limited response rates in the treatment of liver metastases.
Objectives: To investigate the feasibility of radiomics models for predicting the source of hepatic metastases from gastrointestinal (GI) vs. non-gastrointestinal (non-GI) primary tumors on contrast enhanced CT(CECT).
Methods: 347 patients with liver metastases (180 from GI and 167 from non-GI) and abdominal CECT including arterial, portal venous, and delayed phases were divided into training (221) and validation (96) sets at a ratio of 7:3 and an independent testing set (30).
Introduction: Resection of primary tumor and liver metastases is the gold standard for colorectal cancer with liver-only metastases (CRLM). Although treatment options have expanded to enable conversion of unresectable to resectable CRLM, about 40% of patients will have definitively unresectable disease. Major advances in surgical techniques, immunosuppressive protocols and patient selection criteria for liver transplantation have resulted in improved outcomes.
Gallbladder adenocarcinoma has a high mortality rate, with approximately 1.7% cancer-related deaths worldwide. Cancer-associated thrombosis (CAT), including deep vein thrombosis (DVT), can significantly increase the risk of mortality within cancer patients, especially in pancreatic, brain, and intra-abdominal cancers, as well as in advanced and metastatic cancers.
Liver metastasis is the primary factor contributing to unfavorable prognosis in colorectal cancer (CRC). Although N-glycosylation is implicated in metastasis, there is a notable paucity of comprehensive studies addressing the N-glycosylation proteomics associated with liver metastasis in CRC. In this study, N-glycosylated proteins and N-glycosylation sites of differential expression between primary lesions and paired liver metastatic lesions are identified.
Background: Colorectal cancer (CRC) frequently metastasizes to the liver, significantly worsening patient outcomes. While hepatectomy offers the best curative option for colorectal liver metastases (CRLM), margin recurrence remains a major challenge post-surgery. Intraoperative ultrasound (IOUS) aids tumor identification and margin determination, but its limitations in laparoscopic surgery necessitate additional methods.
